Acceleron Pharma Inc. (XLRN) — Overweight

Correction: Ends 1Q:14 w/ Cash of $214 Million; Multiple Data Read-outs in June

CONCLUSION

Acceleron ended 1Q:14 with $214.1 million. Celgene purchased 1.1 million shares of XLRN on May 5th from existing shareholders, so the company received no proceeds (we had previously incorrectly published that Celgene had bought these shares from the company). Acceleron will present two posters on wholly-owned dalantercept in renal cell carcinoma (RCC) in combination with axtinib as well as head & neck at ASCO at the end of the month. We also expect to see Phase II data on both sotatercept and ACE-536 at the European Hematology Association (EHA) meeting in Milan next month. We reiterate our Overweight rating and price target of $65.

- **Correction: Cash of $214 million.** Acceleron ended 1Q:14 with cash of $214.1 million including net proceeds of $129 million received in a January follow-on offering. On May 5, Celgene purchased 1.1 million shares of XLRN for $47.1 million from exisiting shareholders, bringing their ownership position to 14.6% of Acceleron. Acceleron received no proceeds from the transaction.

- **Dalantercept data at ASCO.** Acceleron provided a first look at data from the RCC and head & neck cancer Phase II studies of dalantercept that will be presented at the American Society of Oncology (ASCO) annual meeting being held May 30-June 3 in Chicago. Part 1 of the Phase II RCC trial was a dose escalation study (Abstract #4566). In 20 evaluable RCC patients, dalantercept in combination with INLYTA (axtinib) achieved an objective response rate (ORR) of 25% (5/20 patients) and 10 patients had stable disease equating to a disease control rate (DCR) of 75%. There were no dose-limiting toxicities. Based on these results, Acceleron has selected the dose to be used in Part 2 of this study, which should begin shortly in 130 RCC patients. In 40 evaluable heavily pre-treated squamous head & neck cancer patients (Abstract #6045), dalantercept achieved a DCR of 45%. The benefit from therapy was dose dependent with a 48.1% DCR in 1.2 mg/kg patients and 38.5% in the 0.6mg/kg group. Median overall survival (OS) was 9.5 months at the higher dose and 7.1 at the lower dose. Typically, head & neck cancer patients at similar staging would have a mean OS of ~5.9 months. Investigators will also report data on dalantercept in endometrial cancer (Abstract #5594), although the study showed limited monotherapy activity. Dalantercept will likely be further examined in this cancer as part of a combination therapy. The company expects to initiate a Phase Ib dalantercept trial in HCC in the near-term.

RISKS TO ACHIEVEMENT OF PRICE TARGET

Sotatercept, ACE-536 and/or dalantercept may fail in the clinic or to gain regulatory approval. The Celgene partnership may falter. Acceleron may require additional capital or could face future unforeseen litigation.

COMPANY DESCRIPTION

Acceleron is developing novel drugs for hematology and cancer.

PRICE: US$31.56
TARGET: US$65.00
Proj. EV of $1.9B + YE:14E net cash

Edward A. Tenthoff
Sr Research Analyst, Piper Jaffray & Co.
212 284-9403, edward.a.tenthoff@pjc.com

David N. Lebowitz, CFA
Research Analyst, Piper Jaffray & Co.
212 284-9401, david.n.lebowitz@pjc.com

Changes	Previous	Current
Rating	—	Overweight
Price Tgt	—	US$65.00
FY14E Rev (mil)	—	US$22.5
FY15E Rev (mil)	—	US$20.4
FY14E EPS	US$(1.44)	US$(1.47)
FY15E EPS	US$(1.92)	US$(1.98)

52-Week High / Low	US$57.89 / US$15.00
Shares Out (mil)	31.5
Market Cap. (mil)	US$994.1
Avg Daily Vol (000)	320
Book Value/Share	US$5.74
Net Cash Per Share	US$6.81
Debt to Total Capital	0%
Div (ann)	NA
Fiscal Year End	Dec

Price Performance - 1 Year

Source: Bloomberg

YEAR	REVENUE (US$ m)						EARNINGS PER SHARE (US$)					
	Mar	Jun	Sep	Dec	FY	FY RM	Mar	Jun	Sep	Dec	FY	FY P/E
2013A	15.0	26.4	4.1	11.1	56.7	17.5x	0.13	0.64	(0.54)	(0.21)	(0.07)	NM
2014E	3.3A	3.0	3.1	13.1	22.5	44.2x	(0.30)A	(0.46)	(0.49)	(0.22)	(1.47)	NM
2015E	—	—	—	—	20.4	48.7x	—	—	—	—	(1.98)	NM

- **After ASCO, Focus Will Turn Back To Anemia Franchise.** At the European Hematology Association (EHA) meeting being held June 12th-15th, we expect to see updated Phase II data evaluating both Sotatercept and ACE-536 in beta-thalassemia. We also expect to see data evaluating ACE-536 in myelodysplastic syndrome (MDS). After recent data showing activity for sotatercept in anemia for end-stage renal disease (ESRD) patients, partner Celgene is initiating a Phase II ESRD study with a 60-patient dose-escalation and 230-patient randomized control study versus ESA. The companies also intend to present pre-clinical data for ACE-536 in sickle cell disease that point to some potential in this challenging indication. Celgene is responsible for all costs of these drugs going forward with Acceleron retaining co-promote rights in North America and low-to-mid 20% royalties. We anticipate Celgene will begin a Phase III trial in Beta-thalassemia in late 2014 or early 2015.

- **ACE-083 Phase I To Start 2H:14.** Acceleron is prepping to submit an IND for this compound as a therapy that encourages both increased physical strength in addition to muscle mass.

Edward A. Tenthoff
Piper Jaffray Co.

(212) 284-9403
edward.a.tenthoff@pjc.com

Acceleron Pharma Inc.
Quarterly Earnings Estimates
($ in thousands, except per share data)

5/15/2014

	1QA	2QA	3QE	4QE	2013E	1QA	2QE	3QE	4QE	2014E	2015E
Collaboration Revenue:											
License and milestone	$12,515	$22,891	$625	$7,625	$43,656	$0	$0	$100	$10,100	$10,200	$10,400
Cost-sharing, net	2,497	3,537	3,500	3,500	13,034	3,307	3,000	3,000	3,000	12,307	10,000
Total Revenues	**$15,012**	**$26,428**	**$4,125**	**$11,125**	**$56,690**	**$3,307**	**$3,000**	**$3,100**	**$13,100**	**$22,507**	**$20,400**
Operating Expenses:											
Research and Development	8,780	8,911	9,500	10,000	37,191	11,765	12,500	13,000	14,000	51,265	60,000
General and Administrative	3,096	3,365	3,500	4,000	13,961	3,750	4,000	4,500	5,000	17,250	20,000
Total Operating Expenses	**$11,876**	**$12,276**	**$13,000**	**$14,000**	**$51,152**	**$15,515**	**$16,500**	**$17,500**	**$19,000**	**$68,515**	**$80,000**
Operating Income/(Loss)	**$3,136**	**$14,152**	**($8,875)**	**($2,875)**	**$5,538**	**($12,208)**	**($13,500)**	**($14,400)**	**($5,900)**	**($46,008)**	**($59,600)**
Operating Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Total Other Income/(Expense)[1]	(422)	(641)	(3,075)	(2,950)	(7,088)	3,088	(1,050)	(1,100)	(1,150)	(212)	(5,100)
Pretax Income/(Loss)	**$2,714**	**$13,511**	**($11,950)**	**($5,825)**	**($1,550)**	**($9,120)**	**($14,550)**	**($15,500)**	**($7,050)**	**($46,220)**	**($64,700)**
Pretax Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Income Tax	0	0	0	0	0	0	0	0	0	0	0
Tax Rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net Income/(Loss)	**$2,714**	**$13,511**	**($11,950)**	**($5,825)**	**($1,550)**	**($9,120)**	**($14,550)**	**($15,500)**	**($7,050)**	**($46,220)**	**($64,700)**
Net Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Net Income/(Loss) per Share	**$0.13**	**$0.64**	**($0.54)**	**($0.21)**	**($0.07)**	**($0.30)**	**($0.46)**	**($0.49)**	**($0.22)**	**($1.47)**	**($1.98)**
Basic Shares Outstanding	20,954	20,954	22,250	28,250	23,102	30,321	31,500	31,750	32,000	31,393	32,650

Source: Company reports and Piper Jaffray & Co. analysis.
Note: Acceleron competed its IPO on September 18, 2013 and has not yet provided fully quarterly results for 2012.
1. 2012, 1Q:13 and 2Q:13 Total Other Income/(Expense) line incl. extinguishment of convertible preferred stock and change in fair value of warrants.

Current disclosure information for this company can be found at http://www.piperjaffray.com/researchdisclosures.

IMPORTANT RESEARCH DISCLOSURES



Notes: The boxes on the Rating and Price Target History chart above indicate the date of the Research Note, the rating, and the price target. Each box represents a date on which an analyst made a change to a rating or price target, except for the first box, which may only represent the first Note written during the past three years.

Legend:
I: Initiating Coverage
R: Resuming Coverage
T: Transferring Coverage
D: Discontinuing Coverage
S: Suspending Coverage
OW: Overweight
N: Neutral
UW: Underweight
NA: Not Available
UR: Under Review

Distribution of Ratings/IB Services
Piper Jaffray

			IB Serv./Past 12 Mos.	
Rating	Count	Percent	Count	Percent
BUY [OW]	355	61.74	88	24.79
HOLD [N]	203	35.30	20	9.85
SELL [UW]	17	2.96	0	0.00

Note: Distribution of Ratings/IB Services shows the number of companies currently in each rating category from which Piper Jaffray and its affiliates received compensation for investment banking services within the past 12 months. FINRA rules require disclosure of which ratings most closely correspond with "buy," "hold," and "sell" recommendations. Piper Jaffray ratings are not the equivalent of buy, hold or sell, but instead represent recommended relative weightings. Nevertheless, Overweight corresponds most closely with buy, Neutral with hold and Underweight with sell. See Stock Rating definitions below.

Analyst Certification — Edward A. Tenthoff, Sr Research Analyst
— David N. Lebowitz, CFA, Research Analyst

The views expressed in this report accurately reflect my personal views about the subject company and the subject security. In addition, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report.

Research Disclosures

Piper Jaffray was making a market in the securities of Acceleron Pharma Inc. at the time this research report was published. Piper Jaffray will buy and sell Acceleron Pharma Inc. securities on a principal basis.

Piper Jaffray expects to receive or intends to seek compensation for investment banking services from Acceleron Pharma Inc. in the next 3 months.

Piper Jaffray has received compensation for investment banking services from or has had a client relationship with Acceleron Pharma Inc. within the past 12 months.

Within the past 12 months Piper Jaffray was a managing underwriter of a public offering of, or dealer manager of a tender offer for, the securities of Acceleron Pharma Inc. or the securities of an affiliate.

Within the past 3 years Piper Jaffray participated in a public offering of, or acted as a dealer manager for, Acceleron Pharma Inc. securities.

Piper Jaffray research analysts receive compensation that is based, in part, on overall firm revenues, which include investment banking revenues.

Rating Definitions

Stock Ratings: Piper Jaffray ratings are indicators of expected total return (price appreciation plus dividend) within the next 12 months. At times analysts may specify a different investment horizon or may include additional investment time horizons for specific stocks. Stock performance is measured relative to the group of stocks covered by each analyst. Lists of the stocks covered by each are available at www.piperjaffray.com/researchdisclosures. Stock ratings and/or stock coverage may be suspended from time to time in the event that there is no active analyst opinion or analyst coverage, but the opinion or coverage is expected to resume. Research reports and ratings should not be relied upon as individual investment advice. As always, an investor's decision to buy or sell a security must depend on individual circumstances, including existing holdings, time horizons and risk tolerance. Piper Jaffray sales and trading personnel may provide written or oral commentary, trade ideas, or other information about a particular stock to clients or internal trading desks reflecting different opinions than those expressed by the research analyst. In addition, Piper Jaffray technical research products are based on different methodologies and may contradict the opinions contained in fundamental research reports.

- **Overweight (OW):** Anticipated to outperform relative to the median of the group of stocks covered by the analyst.
- **Neutral (N):** Anticipated to perform in line relative to the median of the group of stocks covered by the analyst.
- **Underweight (UW):** Anticipated to underperform relative to the median of the group of stocks covered by the analyst.

Other Important Information

The material regarding the subject company is based on data obtained from sources we deem to be reliable; it is not guaranteed as to accuracy and does not purport to be complete. This report is solely for informational purposes and is not intended to be used as the primary basis of investment decisions. Piper Jaffray has not assessed the suitability of the subject company for any person. Because of individual client requirements, it is not, and it should not be construed as, advice designed to meet the particular investment needs of any investor. This report is not an offer or the solicitation of an offer to sell or buy any security. Unless otherwise noted, the price of a security mentioned in this report is the market closing price as of the end of the prior business day. Piper Jaffray does not maintain a predetermined schedule for publication of research and will not necessarily update this report. Piper Jaffray policy generally prohibits research analysts from sending draft research reports to subject companies; however, it should be presumed that the analyst(s) who authored this report has had discussions with the subject company to ensure factual accuracy prior to publication, and has had assistance from the company in conducting diligence, including visits to company sites and meetings with company management and other representatives.

Notice to customers: This material is not directed to, or intended for distribution to or use by, any person or entity if Piper Jaffray is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to such person or entity. Customers in any of the jurisdictions where Piper Jaffray and its affiliates do business who wish to effect a transaction in the securities discussed in this report should contact their local Piper Jaffray representative. **Europe:** This material is for the use of intended recipients only and only for distribution to professional and institutional investors, i.e. persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom, or persons who have been categorised by Piper Jaffray Ltd. as professional clients under the rules of the Financial Conduct Authority. **United States:** This report is distributed in the United States by Piper Jaffray & Co., member SIPC, FINRA and NYSE, Inc., which accepts responsibility for its contents. The securities described in this report may not have been registered under the U.S. Securities Act of 1933 and, in such case, may not be offered or sold in the United States or to U.S. persons unless they have been so registered, or an exemption from the registration requirements is available.

This report is produced for the use of Piper Jaffray customers and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose without the prior consent of Piper Jaffray & Co. Additional information is available upon request.